AbbVie Enters a Licensing Deal with IGI Therapeutics for ISB 2001

Shots:AbbVie and IGI Therapeutics, a subsidiary of Ichnos Glenmark Innovation, have entered into an exclusive licensing deal for ISB 2001, a drug targeting oncology & autoimmune diseases developed using IGI's proprietary BEAT protein platformAs per the deal, AbbVie will obtain exclusive rights to develop, manufacture, and commercialize ISB 2001 across North America, Europe,…

ByDipanshu DixitJuly 11, 2025

News

AbbVie to Acquire Capstan Therapeutics for ~$2.1B

Shots:AbbVie has entered into a definitive agreement to acquire Capstan Therapeutics, including its P-I CPTX2309 and proprietary tLNP platform for in vivo RNA delivery to treat B-cell-mediated autoimmune diseasesAs per the deal, Capstan will receive up to $2.1B in cash, pending customary closing conditions and regulatory approvalsCPTX2309 is a tLNP delivering mRNA…

ByDipanshu DixitJuly 1, 2025

News

Torrent Pharma to Acquire a Controlling Stake in JB Chemicals & Pharmaceuticals from KKR for ~$3B

Shots:Torrent Pharma acquired a controlling stake in JB Pharma from KKR in a strategic move to build a diversified healthcare platformAs per the deal, KKR will receive INR 25,689 crore (~$3B) Equity Valuation on a fully diluted basis. Torrent will acquire a 46.39% stake in JB Pharma for ₹11,917 crore (~$1.39B) at INR 1,600…

ByDipanshu DixitJuly 1, 2025

News

AstraZeneca to acquire EsoBiotec for ~$1B

Shots:AstraZeneca to acquire EsoBiotec, which will operate as AstraZeneca’s subsidiary, while maintaining its operations in Belgium to advance cell therapy As per the deal, AstraZeneca will acquire all outstanding equity of EsoBiotec on a cash & debt-free basis for ~$1B, incl. $425M upfront at closing & ~$575M in development & regulatory milestones; closing…

ByRidhi RastogiMarch 18, 2025

News

Zealand Pharma and Roche enter a ~$5.3B Deal to Co-Develop and Commercialize Petrelintide for Weight Management

Shots:Zealand Pharma & Roche will develop & market petrelintide & its products incl. petrelintide + CT-388 (Roche’s asset) in the US & EU for weight loss, with Roche obtaining exclusive marketing rights in the rest of the world Zealand will handle ~50% marketing in the US & EU with opt-in/out rights under specific…

ByRidhi RastogiMarch 12, 2025

News

Pierre Fabre Laboratories and RedRidge Bio Enter R&D Collaboration & License Agreement for Biparatopic Antibody (BPA) Candidates

Shots:Pierre Fabre has partnered with RedRidge for BPA drugs against various targets in oncology, dermatology & rare diseases, where the latter will engineer, screen, & characterize BPAs for jointly selected targets, while Pierre will advance 2 co-development programs As per the deal, RedRidge will hold marketing rights in the US, Canada, & Japan…

ByRidhi RastogiMarch 12, 2025

News

Ono Pharma and Ionis Enter into License Agreement for Sapablursen to Treat Polycythemia Vera

Shots:Ionis has granted Ono Pharma an exclusive global license to develop & commercialize sapablursen for the treatment of polycythemia vera (PV) As per the deal, Ionis will get $280M upfront & ~$660M in development, regulatory & sales milestones, plus mid-teens net sales-based royalties as well as Ionis will be responsible to complete ongoing…

ByRidhi RastogiMarch 12, 2025

AbbVie Enters a Licensing Deal with IGI Therapeutics for ISB 2001

AbbVie to Acquire Capstan Therapeutics for ~$2.1B

Torrent Pharma to Acquire a Controlling Stake in JB Chemicals & Pharmaceuticals from KKR for ~$3B

AstraZeneca to acquire EsoBiotec for ~$1B

Zealand Pharma and Roche enter a ~$5.3B Deal to Co-Develop and Commercialize Petrelintide for Weight Management

Pierre Fabre Laboratories and RedRidge Bio Enter R&D Collaboration & License Agreement for Biparatopic Antibody (BPA) Candidates

Ono Pharma and Ionis Enter into License Agreement for Sapablursen to Treat Polycythemia Vera

Contact US

OUR INFORMATION

FOLLOW US